undamentalytics Newsletter
Sign in

Spero Therapeutics, Inc. balance sheet

At the end of fiscal 2025, Spero Therapeutics, Inc. had total assets of $68.9m, total liabilities of $9.9m and shareholders' equity of $59.0m. It held $40.3m in cash against $91,000 of debt: net cash of $40.2m.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash and equivalents108734308511310976534051
Total current assets1292124951391581141311076752
Total assets14931291061531711251821116953
Accounts payable13441111710
Deferred revenue (current)————024200—
Total current liabilities781227141922374998
Total debt00000000000
Total liabilities7913322183497564109
Shareholders' equity−4585116751328876107465944
Non-controlling interests and other (assets − liabilities − equity)52——————————
Net debt (negative = net cash)−10−87−34−29−85−112−109−76−53−40−51
Shares outstanding——17m19m—32m—53m55m56m58m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: EDIT vs SPROSPRO vs STROOCUL vs SPRO

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Spero Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Spero Therapeutics, Inc.